Stocks Health care ORIC
NASDAQ · Health careOric Pharmaceuticals, Inc. (ORIC)
It posted a net loss of $140.4M. In fiscal 2025 capital spending exceeded operating cash flow by $111.7M. At June 30, 2026 it held $37.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 3, 2026.
Key facts about Oric Pharmaceuticals, Inc.
- Net worth
- Oric Pharmaceuticals, Inc. has a market value (market cap) of $968.6M at the latest share price, and shareholders' equity of $381.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $111M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 3, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Oric Pharmaceuticals, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Oric Pharmaceuticals, Inc. does
Oric Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ORIC.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$129.5M | -$1.47 | -$111.7M |
| 2024 | n/a | -$127.8M | -$1.83 | -$113.9M |
| 2023 | n/a | -$100.7M | -$1.96 | -$86.5M |
| 2022 | n/a | -$89.1M | -$2.25 | -$77.2M |
| 2021 | n/a | -$78.7M | -$2.07 | -$60.5M |
| 2020 | n/a | -$73.7M | -$3.36 | -$45.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Oric Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 23, 2026
- August 3, 2026
- August 3, 2026
- July 30, 2026
- July 30, 2026
- June 22, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Oric Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.5M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 20, 2026 | Piscitelli DominicChief Financial Officer | Exercised options | 14,000 | $61K |
| October 20, 2026 | Piscitelli DominicChief Financial Officer | Soldpre-planned (10b5-1) | 14,000 | $189.4K |
| October 1, 2026 | Heyman Richard A.Director | Exercised options | 3,500 | $5.6K |
| October 1, 2026 | Heyman Richard A.Director | Soldpre-planned (10b5-1) | 3,500 | $45.2K |
| October 1, 2026 | Heyman Richard A.Director | Soldpre-planned (10b5-1), indirect | 3,200 | $41.3K |
| September 28, 2026 | Piscitelli DominicChief Financial Officer | Exercised options | 13,400 | $58.4K |
| September 28, 2026 | Piscitelli DominicChief Financial Officer | Soldpre-planned (10b5-1) | 13,400 | $181.3K |
| September 24, 2026 | Piscitelli DominicChief Financial Officer | Exercised options | 600 | $2.6K |
Who owns ORIC
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Nextech Crossover I GP S.a. r.l.13G, passive with 4 related filers | 8.4% | August 14, 2025 |
| Viking Global Investors LP13G, passive with 9 related filers | 7.8% | May 15, 2026 |
| Nextech Crossover I SCSp13G, passive with 4 related filers | 7.5% | November 14, 2024 |
| EcoR1 Capital, LLC13G, passive with 2 related filers | 6.9% | August 5, 2025 |
| T. Rowe Price Associates, Inc.13G, passive | 5.4% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 181 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Nextech Invest Ltd. | 7,162,637 | 0 |
| BlackRock, Inc. | 6,823,973 | +839,421 |
| EcoR1 Capital, LLC | 6,728,116 | 0 |
| Viking Global Investors LP | 5,126,762 | -697,771 |
| State Street Corp | 4,894,000 | +1,191,804 |
| SR One Capital Management, LP | 4,615,384 | +100,455 |
| Venrock Adviser, LLC | 4,319,765 | 0 |
| NEA Management Company, LLC | 4,118,621 | 0 |
| Vanguard Capital Management LLC | 3,951,169 | +264,162 |
| AIHC Capital Management Ltd | 3,828,460 | +1,368,909 |
| Alkeon Capital Management LLC | 3,739,096 | -765,000 |
| Column Group LLC | 3,540,777 | 0 |
| Siren, L.L.C. | 2,998,192 | 0 |
| Fmr LLC | 2,635,475 | +201,395 |
| Citadel Advisors LLC | 2,595,299 | +172,558 |
| Goldman Sachs Group Inc | 2,451,796 | +976,084 |
| Geode Capital Management, LLC | 2,090,089 | +251,288 |
| First Turn Management, LLC | 2,017,284 | 0 |
| Orbimed Advisors LLC | 2,015,000 | -678,929 |
| Integral Health Asset Management, LLC | 1,900,000 | +500,000 |
Insiders
5 insiders reported holding 1,045,660 shares in total, about $9.8M at the last price.
| Holder | Shares |
|---|---|
| Chacko JacobPRESIDENT AND CEO, Director | 581,711 |
| Heyman Richard A.Director | 241,772203,472 held indirectly |
| Kunkel Lori AnneDirector | 84,200 |
| Piscitelli DominicChief Financial Officer | 69,828 |
| Multani Pratik SChief Medical Officer | 68,149 |
Questions about ORIC
What does Oric Pharmaceuticals, Inc. do?
Oric Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as ORIC. Its shares trade on NASDAQ under the ticker ORIC.
What is Oric Pharmaceuticals, Inc.'s net worth?
Oric Pharmaceuticals, Inc. has a market value (market cap) of $968.6M at the latest share price, and shareholders' equity of $381.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Oric Pharmaceuticals, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $140.4M.
When did Oric Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 3, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from October 23, 2026.
When is Oric Pharmaceuticals, Inc.'s next earnings report?
Oric Pharmaceuticals, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ORIC with
Follow ORIC
Get an email when Oric Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Oric Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.